DE60223262T2 - Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis - Google Patents
Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis Download PDFInfo
- Publication number
- DE60223262T2 DE60223262T2 DE60223262T DE60223262T DE60223262T2 DE 60223262 T2 DE60223262 T2 DE 60223262T2 DE 60223262 T DE60223262 T DE 60223262T DE 60223262 T DE60223262 T DE 60223262T DE 60223262 T2 DE60223262 T2 DE 60223262T2
- Authority
- DE
- Germany
- Prior art keywords
- fucan
- use according
- composition
- fucoidan
- administration
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010003246 arthritis Diseases 0.000 title abstract description 13
- 201000004681 Psoriasis Diseases 0.000 title abstract description 11
- 238000011282 treatment Methods 0.000 title description 11
- 229920000855 Fucoidan Polymers 0.000 claims abstract description 69
- 239000000203 mixture Substances 0.000 claims abstract description 30
- 208000031737 Tissue Adhesions Diseases 0.000 claims abstract description 20
- 201000010099 disease Diseases 0.000 claims description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 23
- 239000003814 drug Substances 0.000 claims description 20
- 241001465754 Metazoa Species 0.000 claims description 13
- 239000002552 dosage form Substances 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 10
- 108091034117 Oligonucleotide Proteins 0.000 claims description 10
- 239000000499 gel Substances 0.000 claims description 10
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 7
- 238000013270 controlled release Methods 0.000 claims description 7
- -1 etopside Chemical compound 0.000 claims description 7
- 239000007943 implant Substances 0.000 claims description 7
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 claims description 6
- 229920001661 Chitosan Polymers 0.000 claims description 6
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims description 6
- MJVAVZPDRWSRRC-UHFFFAOYSA-N Menadione Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1 MJVAVZPDRWSRRC-UHFFFAOYSA-N 0.000 claims description 6
- 239000013543 active substance Substances 0.000 claims description 6
- KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 claims description 6
- 229960000485 methotrexate Drugs 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- VCMMXZQDRFWYSE-UHFFFAOYSA-N plumbagin Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1O VCMMXZQDRFWYSE-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- 108090000994 Catalytic RNA Proteins 0.000 claims description 5
- 102000053642 Catalytic RNA Human genes 0.000 claims description 5
- PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 5
- 108010036949 Cyclosporine Proteins 0.000 claims description 5
- 229930012538 Paclitaxel Natural products 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- 229960001265 ciclosporin Drugs 0.000 claims description 5
- 229930182912 cyclosporin Natural products 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003112 inhibitor Substances 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 229960001592 paclitaxel Drugs 0.000 claims description 5
- 229920001223 polyethylene glycol Polymers 0.000 claims description 5
- 108091092562 ribozyme Proteins 0.000 claims description 5
- 239000007921 spray Substances 0.000 claims description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 239000000074 antisense oligonucleotide Substances 0.000 claims description 4
- 238000012230 antisense oligonucleotides Methods 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229960004679 doxorubicin Drugs 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 238000007918 intramuscular administration Methods 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000004005 microsphere Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 238000007920 subcutaneous administration Methods 0.000 claims description 4
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 claims description 3
- ZMOIGGHUSNHCAB-UHFFFAOYSA-N Isoplumbagin Natural products C1=CC(O)=C2C(=O)C(C)=CC(=O)C2=C1 ZMOIGGHUSNHCAB-UHFFFAOYSA-N 0.000 claims description 3
- UETNIIAIRMUTSM-UHFFFAOYSA-N Jacareubin Natural products CC1(C)OC2=CC3Oc4c(O)c(O)ccc4C(=O)C3C(=C2C=C1)O UETNIIAIRMUTSM-UHFFFAOYSA-N 0.000 claims description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 3
- ALPCEXCHMFUSAN-UHFFFAOYSA-N beta-Dihydroplumbagin Natural products C1=CC=C2C(=O)C(C)CC(=O)C2=C1O ALPCEXCHMFUSAN-UHFFFAOYSA-N 0.000 claims description 3
- VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 claims description 3
- 229960001338 colchicine Drugs 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 229960003668 docetaxel Drugs 0.000 claims description 3
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001156 mitoxantrone Drugs 0.000 claims description 3
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims description 3
- 150000004492 retinoid derivatives Chemical class 0.000 claims description 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims description 3
- 229960002930 sirolimus Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-QZQOTICOSA-N sulfasalazine Chemical compound C1=C(O)C(C(=O)O)=CC(\N=N\C=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-QZQOTICOSA-N 0.000 claims description 3
- 229960001940 sulfasalazine Drugs 0.000 claims description 3
- NCEXYHBECQHGNR-UHFFFAOYSA-N sulfasalazine Natural products C1=C(O)C(C(=O)O)=CC(N=NC=2C=CC(=CC=2)S(=O)(=O)NC=2N=CC=CC=2)=C1 NCEXYHBECQHGNR-UHFFFAOYSA-N 0.000 claims description 3
- 235000012711 vitamin K3 Nutrition 0.000 claims description 3
- 239000011652 vitamin K3 Substances 0.000 claims description 3
- 229940041603 vitamin k 3 Drugs 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 2
- 229940048053 acrylate Drugs 0.000 claims description 2
- 229940072056 alginate Drugs 0.000 claims description 2
- 239000011505 plaster Substances 0.000 claims description 2
- 229920001983 poloxamer Polymers 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 16
- 210000004027 cell Anatomy 0.000 description 38
- 239000010408 film Substances 0.000 description 24
- 210000000440 neutrophil Anatomy 0.000 description 19
- 230000000694 effects Effects 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 15
- 229940079593 drug Drugs 0.000 description 15
- 239000012528 membrane Substances 0.000 description 15
- 230000033115 angiogenesis Effects 0.000 description 14
- 210000004379 membrane Anatomy 0.000 description 14
- 230000005764 inhibitory process Effects 0.000 description 12
- 230000015572 biosynthetic process Effects 0.000 description 11
- 239000006072 paste Substances 0.000 description 11
- 229920001610 polycaprolactone Polymers 0.000 description 11
- 239000000243 solution Substances 0.000 description 10
- 230000004913 activation Effects 0.000 description 9
- 235000013601 eggs Nutrition 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 108060005980 Collagenase Proteins 0.000 description 8
- 102000029816 Collagenase Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- 230000004663 cell proliferation Effects 0.000 description 7
- 229960002424 collagenase Drugs 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 6
- 230000012010 growth Effects 0.000 description 6
- 230000004054 inflammatory process Effects 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 108091007196 stromelysin Proteins 0.000 description 6
- 210000002437 synoviocyte Anatomy 0.000 description 6
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 102000009123 Fibrin Human genes 0.000 description 5
- 108010073385 Fibrin Proteins 0.000 description 5
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 5
- 239000012981 Hank's balanced salt solution Substances 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 102000016611 Proteoglycans Human genes 0.000 description 5
- 108010067787 Proteoglycans Proteins 0.000 description 5
- 230000001772 anti-angiogenic effect Effects 0.000 description 5
- 230000001093 anti-cancer Effects 0.000 description 5
- 230000003110 anti-inflammatory effect Effects 0.000 description 5
- 210000001612 chondrocyte Anatomy 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 229950003499 fibrin Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 239000008188 pellet Substances 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 5
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000005038 ethylene vinyl acetate Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229920003023 plastic Polymers 0.000 description 4
- 239000004033 plastic Substances 0.000 description 4
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 238000001890 transfection Methods 0.000 description 4
- 230000008733 trauma Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- KAQXCFRYVVJPEV-UHFFFAOYSA-N 2,4-dimethyl-1,3-thiazole;1,5-diphenyl-1h-tetrazol-1-ium;bromide Chemical compound [Br-].CC1=CSC(C)=N1.C1=CC=CC=C1[NH+]1C(C=2C=CC=CC=2)=NN=N1 KAQXCFRYVVJPEV-UHFFFAOYSA-N 0.000 description 3
- 229920002307 Dextran Polymers 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 229920002385 Sodium hyaluronate Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 230000001028 anti-proliverative effect Effects 0.000 description 3
- 239000003435 antirheumatic agent Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 230000008021 deposition Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 210000004969 inflammatory cell Anatomy 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000004632 polycaprolactone Substances 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 230000008439 repair process Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 229940010747 sodium hyaluronate Drugs 0.000 description 3
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 229930105110 Cyclosporin A Natural products 0.000 description 2
- 108010000912 Egg Proteins Proteins 0.000 description 2
- 102000002322 Egg Proteins Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102000005741 Metalloproteases Human genes 0.000 description 2
- 108010006035 Metalloproteases Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108090000190 Thrombin Proteins 0.000 description 2
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 2
- 238000011256 aggressive treatment Methods 0.000 description 2
- 230000002491 angiogenic effect Effects 0.000 description 2
- 229940124346 antiarthritic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 210000000038 chest Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000001647 drug administration Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- 229960005420 etoposide Drugs 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 108010042430 galactose receptor Proteins 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 208000000509 infertility Diseases 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 231100000535 infertility Toxicity 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 208000003243 intestinal obstruction Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000011859 microparticle Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229940105132 myristate Drugs 0.000 description 2
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000007310 pathophysiology Effects 0.000 description 2
- 239000002644 phorbol ester Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000001525 retina Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 230000003637 steroidlike Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 230000002459 sustained effect Effects 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 229960004072 thrombin Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 206010000050 Abdominal adhesions Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 241000766026 Coregonus nasus Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 229920004937 Dexon® Polymers 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 208000004483 Dyspareunia Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 229920000544 Gore-Tex Polymers 0.000 description 1
- 240000007058 Halophila ovalis Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001111421 Pannus Species 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 206010060932 Postoperative adhesion Diseases 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 238000012084 abdominal surgery Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000004037 angiogenesis inhibitor Substances 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 230000002429 anti-coagulating effect Effects 0.000 description 1
- 230000002391 anti-complement effect Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 108010008730 anticomplement Proteins 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000004019 antithrombin Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010382 chemical cross-linking Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000003837 chick embryo Anatomy 0.000 description 1
- 210000003711 chorioallantoic membrane Anatomy 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 210000003278 egg shell Anatomy 0.000 description 1
- 210000002969 egg yolk Anatomy 0.000 description 1
- 235000013345 egg yolk Nutrition 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- 239000012997 ficoll-paque Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 108010015750 fucose-binding lectin Proteins 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- YQOKLYTXVFAUCW-UHFFFAOYSA-N guanidine;isothiocyanic acid Chemical compound N=C=S.NC(N)=N YQOKLYTXVFAUCW-UHFFFAOYSA-N 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 210000000994 inner shell membrane Anatomy 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000005067 joint tissue Anatomy 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960004184 ketamine hydrochloride Drugs 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 231100000782 microtubule inhibitor Toxicity 0.000 description 1
- 210000004088 microvessel Anatomy 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- WKOVRQFUCLHTHB-UHFFFAOYSA-N n-(ethyliminomethylideneamino)-n-methylmethanamine Chemical compound CCN=C=NN(C)C WKOVRQFUCLHTHB-UHFFFAOYSA-N 0.000 description 1
- 230000014399 negative regulation of angiogenesis Effects 0.000 description 1
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000003101 oviduct Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001023 pro-angiogenic effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000010409 thin film Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 210000005166 vasculature Anatomy 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/042—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31536201P | 2001-08-29 | 2001-08-29 | |
| US315362P | 2001-08-29 | ||
| PCT/CA2002/001337 WO2003018033A1 (en) | 2001-08-29 | 2002-08-29 | Use of fucans in the treatment of adhesions, arthritis and psoriasis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE60223262D1 DE60223262D1 (de) | 2007-12-13 |
| DE60223262T2 true DE60223262T2 (de) | 2008-08-14 |
Family
ID=23224048
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE60223262T Expired - Lifetime DE60223262T2 (de) | 2001-08-29 | 2002-08-29 | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US6812220B2 (https=) |
| EP (1) | EP1420801B1 (https=) |
| JP (2) | JP4758063B2 (https=) |
| KR (2) | KR100910246B1 (https=) |
| CN (2) | CN1319540C (https=) |
| AT (1) | ATE376835T1 (https=) |
| AU (1) | AU2002325113B2 (https=) |
| CA (1) | CA2458853C (https=) |
| DE (1) | DE60223262T2 (https=) |
| DK (1) | DK1420801T3 (https=) |
| ES (1) | ES2295386T3 (https=) |
| MX (1) | MXPA04001876A (https=) |
| NZ (2) | NZ532015A (https=) |
| PT (1) | PT1420801E (https=) |
| WO (1) | WO2003018033A1 (https=) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632456B1 (en) * | 1993-06-24 | 2003-10-14 | Astrazeneca Ab | Compositions for inhalation |
| US7595378B2 (en) | 2001-06-13 | 2009-09-29 | Genmab A/S | Human monoclonal antibodies to epidermal growth factor receptor (EGFR) |
| DK1539157T3 (da) | 2002-09-18 | 2013-10-07 | Univ Pennsylvania | Fremgangsmåde til hæmning af choroidal neovaskularisering |
| US8138265B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| US8137688B2 (en) | 2003-01-10 | 2012-03-20 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| US6982298B2 (en) | 2003-01-10 | 2006-01-03 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| US7465766B2 (en) | 2004-01-08 | 2008-12-16 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| US8221758B2 (en) * | 2003-03-06 | 2012-07-17 | Cellmid Limited | Anti-midkine antibody for preventing post-laparotomy adhesions |
| BRPI0418384A (pt) * | 2003-05-30 | 2007-06-26 | Arc Pharmaceuticals Inc | composições farmacêuticas e métodos referentes à inibição de adesões fibrosas utilizando diversos agentes |
| KR20060085246A (ko) | 2003-09-18 | 2006-07-26 | 마커사이트, 인코포레이티드 | 경공막 전달 |
| JPWO2005089800A1 (ja) * | 2004-03-17 | 2008-01-31 | 株式会社ロコモジェン | ｈｓＨＲＤ３を含む医薬組成物 |
| CA2572804C (en) * | 2004-07-09 | 2013-04-02 | The Cleveland Clinic Foundation | Hydroxyphenyl cross-linked macromolecular network and applications thereof |
| CA2989941A1 (en) * | 2004-09-23 | 2006-03-30 | Arc Pharmaceuticals, Inc. | Pharmaceutical compostions and methods relating to inhibiting fibrous adhesions or inflammatory disease using low sulphate fucans |
| US8663639B2 (en) | 2005-02-09 | 2014-03-04 | Santen Pharmaceutical Co., Ltd. | Formulations for treating ocular diseases and conditions |
| DK1848431T3 (en) | 2005-02-09 | 2016-04-18 | Santen Pharmaceutical Co Ltd | LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS |
| CN101119726B (zh) * | 2005-02-16 | 2011-02-02 | 麦仁斯有限公司 | 用于治疗或预防涉及肥胖、糖尿病、代谢综合症、神经变性疾病和线粒体功能障碍疾病的疾病的药物组合物 |
| US20060210692A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Baby food composition |
| US7776365B2 (en) * | 2005-03-18 | 2010-08-17 | Sakura Properties, Llc | Article with skin protecting and moisturizing compound |
| US20060210514A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Skin protection and moisturizing compositions and method of making the same |
| US20060210697A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Infant formula composition |
| US20060210515A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Hair growth formula |
| US20060210688A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Dehydrated sports drink powder |
| US20060210496A1 (en) * | 2005-03-18 | 2006-09-21 | Mower Thomas E | Compositions for skin protection from ultraviolet damage |
| US20070020358A1 (en) * | 2005-03-18 | 2007-01-25 | Mower Thomas E | Sports drink concentrate |
| US7666448B2 (en) * | 2005-03-18 | 2010-02-23 | Sakura Properties, Llc | Skin cleansing article |
| US7749545B2 (en) * | 2005-03-18 | 2010-07-06 | Sakura Properties, Llc | Fucoidan compositions and methods for dietary and nutritional supplements |
| CA2603785C (en) | 2005-04-15 | 2014-07-22 | Roman Perez-Soler | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
| US20070003669A1 (en) * | 2005-06-02 | 2007-01-04 | Troy Kearl | Fucoidan delivery system |
| WO2007028256A2 (en) * | 2005-09-09 | 2007-03-15 | Les Biotechnologies Oceanova Inc. | Polysaccharides compositions comprising fucans and galactans and their use to reduce extravasation and inflammation |
| KR20140093764A (ko) | 2006-02-09 | 2014-07-28 | 산텐 세이야꾸 가부시키가이샤 | 안정한 제제와 그 제조 및 사용 방법 |
| FR2897538B1 (fr) | 2006-02-23 | 2008-05-02 | Univ Paris Descartes | Utilisation de fucanes a des fins de greffe, d'ingenierie et de regeneration osseuses |
| ES2563288T3 (es) | 2006-03-23 | 2016-03-14 | Santen Pharmaceutical Co., Ltd | Rapamicina en dosis bajas para el tratamiento de enfermedades relacionadas con la permeabilidad vascular |
| JP4814677B2 (ja) * | 2006-03-31 | 2011-11-16 | 株式会社荏原製作所 | 基板保持装置および研磨装置 |
| EP2043685B1 (en) | 2006-07-03 | 2015-12-23 | Genmab A/S | Prevention of rash in patients undergoing anti-egfr therapy |
| EP2249891B1 (en) | 2008-02-13 | 2016-05-25 | The Cleveland Clinic Foundation | Molecular enhancement of extracellular matrix and methods of use |
| US8815953B2 (en) | 2008-03-13 | 2014-08-26 | Spectrum Pharmaceuticals, Inc. | Formulations of vitamin K analogs for topical use |
| US8410180B2 (en) | 2008-04-30 | 2013-04-02 | The Cleveland Clinic Foundation | Methods to treat urinary incontinence |
| US20120071439A1 (en) * | 2009-03-25 | 2012-03-22 | Saburo Minami | Cartilage production promoter and prophylactic or therapeutic agent for diseases associated with cartilage damage |
| JO3676B1 (ar) * | 2009-07-27 | 2020-08-27 | Arc Medical Devices Inc | مركبات صيدلانية تضم فوكانات معدلة وطرق تتعلق بها |
| KR101528265B1 (ko) * | 2010-04-16 | 2015-06-11 | 코웨이 주식회사 | 베타-라파콘을 유효성분으로 포함하는 주름개선용 화장료 조성물 |
| EP2734213B1 (en) * | 2011-07-19 | 2018-06-06 | Baxalta GmbH | Resorption enhancers as additives to improve the oral formulation of non-anticoagulant sulfated polysaccharides |
| JP2018510905A (ja) * | 2015-02-16 | 2018-04-19 | エグザンシャル | 皮膚障害の予防又は治療のための組成物 |
| JP7160683B2 (ja) | 2016-04-29 | 2022-10-25 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 術後癒着の予防及び治療のための方法及び組成物 |
| US11446326B2 (en) * | 2018-07-27 | 2022-09-20 | ARC Medical Devices | Highly sulfated fucans for the treatment of fibrous adhesions |
| US12186334B2 (en) | 2018-07-27 | 2025-01-07 | ARC Medical Inc. | High-molecular-weight fucans for treating fibrous adhesions and other diseases and conditions |
| MX2021000866A (es) | 2019-03-05 | 2021-06-15 | Arc Medical Devices Inc | Sistemas y metodos para la filtracion de flujo tangencial de composiciones viscosas. |
| CN111617030B (zh) * | 2020-05-22 | 2021-09-07 | 广东药科大学 | 壳寡糖口服液及其在制备减肥药物中的应用 |
| WO2025166450A1 (en) * | 2024-02-05 | 2025-08-14 | ARC Medical Inc. | Compositions, devices, systems and methods relating to improvement of range of motion in joints |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3971848A (en) * | 1970-12-21 | 1976-07-27 | Kimitsu Chemical Laboratory Co. Ltd. | Lubricating composition for mucosa or epidermis |
| JPS58147064A (ja) | 1982-02-25 | 1983-09-01 | Fuji Electric Co Ltd | トランジスタ |
| EP0293826A3 (en) | 1987-06-02 | 1989-05-10 | Stichting REGA V.Z.W. | Therapeutic and prophylactic application of sulfated polysaccharides against aids |
| JPS6431707A (en) | 1987-07-28 | 1989-02-02 | Nikko Chemicals | Dermal agent for external use |
| JPH0714850B2 (ja) | 1987-09-29 | 1995-02-22 | 喜郎 板谷 | 化粧料 |
| JPH01313433A (ja) | 1988-06-13 | 1989-12-18 | Nippon Koutai Kenkyusho:Kk | 抗ｈｉｖ剤 |
| JP2853165B2 (ja) * | 1989-05-29 | 1999-02-03 | 味の素株式会社 | 体組織癒着防止膜 |
| FR2648463B1 (fr) * | 1989-06-14 | 1993-01-22 | Inst Fs Rech Expl Mer | Polysaccharides sulfates, agent anticoagulant et agent anticomplementaire obtenus a partir de fucanes d'algues brunes et leur procede d'obtention |
| US6096722A (en) * | 1990-08-14 | 2000-08-01 | Isis Pharmaceuticals Inc. | Antisense modulation of cell adhesion molecule expression and treatment of cell adhesion molecule-associated diseases |
| US5318890A (en) * | 1991-05-06 | 1994-06-07 | The Regents Of The University Of California | Assays for inhibitors of leukocyte adhesion |
| US5605938A (en) * | 1991-05-31 | 1997-02-25 | Gliatech, Inc. | Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate |
| JP3403496B2 (ja) * | 1993-09-24 | 2003-05-06 | 株式会社ヤクルト本社 | 抗潰瘍剤およびヘリコバクター・ピロリの定着阻害剤 |
| JP3545789B2 (ja) * | 1993-09-30 | 2004-07-21 | 味の素ファルマ株式会社 | 腹腔内癒着防止剤 |
| FR2772618B1 (fr) * | 1997-12-18 | 2000-02-18 | Ifremer | Utilisation de fucane comme regulateur de la reconstruction des tissus conjonctifs |
| EP1117835A4 (en) * | 1998-10-02 | 2005-03-09 | Genzyme Corp | PREVENTION OF ADHERENCES |
| JP4267106B2 (ja) * | 1998-10-15 | 2009-05-27 | 株式会社クラレ | 癒着防止用材料 |
| JP2001052309A (ja) | 1999-08-06 | 2001-02-23 | Alps Electric Co Ltd | 薄膜磁気ヘッドおよびその製造方法 |
| SE0001631D0 (sv) * | 2000-05-04 | 2000-05-04 | Sahltech Ab | New use |
-
2002
- 2002-08-28 US US10/232,850 patent/US6812220B2/en not_active Expired - Lifetime
- 2002-08-29 PT PT02758008T patent/PT1420801E/pt unknown
- 2002-08-29 AU AU2002325113A patent/AU2002325113B2/en not_active Ceased
- 2002-08-29 DK DK02758008T patent/DK1420801T3/da active
- 2002-08-29 WO PCT/CA2002/001337 patent/WO2003018033A1/en not_active Ceased
- 2002-08-29 JP JP2003522551A patent/JP4758063B2/ja not_active Expired - Lifetime
- 2002-08-29 KR KR1020047003089A patent/KR100910246B1/ko not_active Expired - Fee Related
- 2002-08-29 CA CA2458853A patent/CA2458853C/en not_active Expired - Lifetime
- 2002-08-29 EP EP02758008A patent/EP1420801B1/en not_active Expired - Lifetime
- 2002-08-29 ES ES02758008T patent/ES2295386T3/es not_active Expired - Lifetime
- 2002-08-29 NZ NZ532015A patent/NZ532015A/en not_active IP Right Cessation
- 2002-08-29 KR KR1020097002751A patent/KR20090019926A/ko not_active Ceased
- 2002-08-29 NZ NZ547609A patent/NZ547609A/en not_active IP Right Cessation
- 2002-08-29 CN CNB028166930A patent/CN1319540C/zh not_active Expired - Fee Related
- 2002-08-29 CN CNA200710096370XA patent/CN101028283A/zh active Pending
- 2002-08-29 MX MXPA04001876A patent/MXPA04001876A/es active IP Right Grant
- 2002-08-29 DE DE60223262T patent/DE60223262T2/de not_active Expired - Lifetime
- 2002-08-29 AT AT02758008T patent/ATE376835T1/de active
-
2004
- 2004-09-13 US US10/940,413 patent/US20050074496A1/en not_active Abandoned
- 2004-10-05 US US10/958,759 patent/US7163930B2/en not_active Expired - Lifetime
-
2009
- 2009-07-21 JP JP2009170270A patent/JP2009280597A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| JP2009280597A (ja) | 2009-12-03 |
| CA2458853C (en) | 2010-10-19 |
| DE60223262D1 (de) | 2007-12-13 |
| CA2458853A1 (en) | 2003-03-06 |
| US7163930B2 (en) | 2007-01-16 |
| ATE376835T1 (de) | 2007-11-15 |
| CN1319540C (zh) | 2007-06-06 |
| NZ547609A (en) | 2008-07-31 |
| HK1066482A1 (en) | 2005-03-24 |
| EP1420801A1 (en) | 2004-05-26 |
| WO2003018033A1 (en) | 2003-03-06 |
| JP2005508893A (ja) | 2005-04-07 |
| AU2002325113B2 (en) | 2006-10-26 |
| NZ532015A (en) | 2006-12-22 |
| US20050074496A1 (en) | 2005-04-07 |
| KR100910246B1 (ko) | 2009-07-31 |
| US20050119216A1 (en) | 2005-06-02 |
| US20030064958A1 (en) | 2003-04-03 |
| JP4758063B2 (ja) | 2011-08-24 |
| KR20090019926A (ko) | 2009-02-25 |
| KR20040032992A (ko) | 2004-04-17 |
| MXPA04001876A (es) | 2004-06-15 |
| EP1420801B1 (en) | 2007-10-31 |
| US6812220B2 (en) | 2004-11-02 |
| CN101028283A (zh) | 2007-09-05 |
| PT1420801E (pt) | 2008-01-17 |
| DK1420801T3 (da) | 2008-03-03 |
| ES2295386T3 (es) | 2008-04-16 |
| CN1547478A (zh) | 2004-11-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60223262T2 (de) | Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis | |
| AU2002325113A1 (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
| US20090220603A1 (en) | Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics | |
| US7129218B2 (en) | Use of rhamnolipids in wound healing, treatment and prevention of gum disease and periodontal regeneration | |
| Liu et al. | Mitomycin C-polyethylene glycol controlled-release film inhibits collagen secretion and induces apoptosis of fibroblasts in the early wound of a postlaminectomy rat model | |
| DE68910973T2 (de) | Arzneimittelzusammensetzung, enthaltend deoxyribonukleoside für heilung von wunden. | |
| US20070238697A1 (en) | Pharmaceutical compositions and methods relating to fucans | |
| DE69814612T2 (de) | Stoffe zur hemmung der bildung des pterygiums und seines postoperative wiederauftretens | |
| DE19903385A1 (de) | Mittel zur Prävention von In-Stent Restenosen und postoperativen Entzündungen | |
| DE602004012894T2 (de) | Oberflächenschutz von frei liegenden biologischen geweben | |
| Hacımüftüoğlu et al. | Rapid wound healing with silver nanoparticle-decorated miswak-derived carbon quantum dots | |
| US7262171B1 (en) | Use of rhamnolipids in wound healing, treating burn shock, atherosclerosis, organ transplants, depression, schizophrenia and cosmetics | |
| EP3032949A1 (de) | Mittel enthaltend mikropartikel zur reinigung und zum schutz von technischen oberflächen | |
| AU2007200318B2 (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
| EP1870105A1 (en) | Use of fucans in the treatment of psoriasis | |
| HK1108566A (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
| HK1066482B (en) | Use of fucans in the treatment of adhesions, arthritis and psoriasis | |
| WO2025199662A1 (es) | Nano-vesículas aisladas de semillas de persea americana y sus usos | |
| DE202023105791U1 (de) | Pflanzliches transdermales Pflaster | |
| SUMIRAN | EVALUATION OF CHITOSAN-POVIDONE IODINE COMPOSITE FILMS ON CUTANEOUS WOUND HEALING IN RABBITS | |
| EP0442063A2 (de) | Verwendung von 2',4',6'-Trimethoxy-4-(1-pyrrolidinyl)butyrophenon zur lokalen Behandlung von trophischen Erkrankungen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |